Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Xilio Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +2 vs. Q3 2025
- Shares held
- 39.7M
- +19.2M (+93.1%) vs. Q3 2025
- Total value
- $25.4M
- +$8.06M (+46.4%) vs. Q3 2025
- New holders
- 11
- 5 more added
- Sold out
- 9
- 5 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 9,105,451 | $5.83M | 0.30% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 7,372,686 | $4.72M | 0.36% | +2,805,869+61.4% | Added |
| Frazier Life Sciences Management, L.P. | 5,915,091 | $3.79M | 0.10% | +5,915,091 | New |
| Point72 Asset Management, L.P. | 4,000,000 | $2.56M | 0.00% | +4,000,000 | New |
| Sio Capital Management, LLC | 2,134,537 | $1.37M | 0.23% | +2,134,537 | New |
| StemPoint Capital LP | 2,030,028 | $1.30M | 0.22% | +2,030,028 | New |
| Merck & Co., Inc. | 1,483,758 | $949.9K | 0.34% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,255,692 | $803.6K | 0.00% | 00.0% | Unchanged |
| Empery Asset Management, LP | 1,183,040 | $757.4K | 0.67% | +1,183,040 | New |
| Ghisallo Capital Management LLC | 1,113,222 | $712.7K | 0.03% | +1,113,222 | New |
| Morgan Stanley | 839,850 | $537.7K | 0.00% | −122,067−12.7% | Reduced |
| AJU IB Investment Co., Ltd. | 667,742 | $427.5K | 2.29% | 00.0% | Unchanged |
| FMR LLC | 511,820 | $327.7K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 436,216 | $279.3K | 0.00% | +436,216 | New |
| Renaissance Technologies LLC | 344,416 | $220.5K | 0.00% | +139,716+68.3% | Added |
| Geode Capital Management, LLC | 328,972 | $210.6K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 186,390 | $119.3K | 0.00% | +22,500+13.7% | Added |
| Velan Capital Investment Management LP | 170,000 | $108.8K | 0.06% | +170,000 | New |
| Gsa Capital Partners LLP | 147,966 | $95.0K | 0.01% | +147,966 | New |
| Stonepine Capital Management, LLC | 126,270 | $80.8K | 0.06% | +126,270 | New |
| Northern Trust Corp | 66,609 | $42.6K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 62,032 | $39.7K | 0.00% | −25,758−29.3% | Reduced |
| Bridgeway Capital Management, LLC | 56,081 | $35.9K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 42,080 | $26.9K | 0.00% | +42,080 | New |
| HRT Financial LP | 31,886 | $20.0K | 0.00% | +7,150+28.9% | Added |
| Mariner, LLC | 25,000 | $16.0K | 0.00% | 00.0% | Unchanged |
| LPL Financial LLC | 21,000 | $13.4K | 0.00% | −10,000−32.3% | Reduced |
| Raymond James Financial Inc | 18,761 | $12.0K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 17,304 | $11.1K | 0.00% | −58,741−77.2% | Reduced |
| Dunhill Financial, LLC | 10,274 | $6.58K | 0.00% | 00.0% | Unchanged |
| Investors Asset Management of Georgia Inc | 10,000 | $6.40K | 0.00% | 00.0% | Unchanged |
| Pinnacle Financial Group, LLC | 10,000 | $6.40K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,037 | $1.30K | 0.00% | 00.0% | Unchanged |
| Key Financial Inc | 830 | $531 | 0.00% | 00.0% | Unchanged |
| Private Wealth Management Group, LLC | 310 | $199 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 261 | $167 | 0.00% | +15+6.1% | Added |
| UBS Group AG | 203 | $130 | 0.00% | −13,449−98.5% | Reduced |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −328,794−100.0% | Sold out |
| Trustees of Columbia University in the City of New York | 0 | $0 | 0.00% | −249,635−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −198,859−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −32,130−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −29,689−100.0% | Sold out |
| Aptus Capital Advisors, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| SevenBridge Financial Group, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Federation des caisses Desjardins du Quebec | 0 | $0 | 0.00% | −3,300−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −258−100.0% | Sold out |
| Takeda Pharmaceutical Co Ltd | – | – | – | – | Not filed |